A carregar...
A Phase II clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer
BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is up-regulated in castration-resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective in inducing apoptosis in prostate cancer cells likely due to the compensatory up-regulation of the androgen receptor (AR) pathw...
Na minha lista:
| Publicado no: | Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4892938/ https://ncbi.nlm.nih.gov/pubmed/27019001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29927 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|